US2020181255A1PendingUtilityA1
Human IL-23 Antigen Binding Proteins

Assignee: AMGEN INCPriority: Oct 26, 2009Filed: Feb 18, 2020Published: Jun 11, 2020
Est. expiryOct 26, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Jennifer E. Towne Janet D. Cheng Jason C. O'Neill Yu Zhang Yu Sun Heather Cerne Derek E. Piper Randal R. Ketchem
A61K 47/6813A61P 37/00A61K 40/00C07K 16/244C07K 16/18A61K 39/3955C07K 16/24C07K 2317/55C07K 2317/24C07K 2317/76C07K 2317/622A61K 47/6845A61K 39/395C07K 2317/92C07K 2317/54C07K 2317/565A61K 2039/505C07K 2317/21C07K 2317/626C07K 2317/31
PatentIndex Score
Cited by
References
Claims
Abstract

Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.
Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated antigen binding protein that binds IL-23, comprising at least one heavy chain variable region comprising a CDRH1, a CDRH2 and a CDRH3 selected from the group consisting of:
 a) a CDRH1 that differs by no more than one amino acid substitution, insertion or deletion from a CDRH1 as shown in TABLE 3;   b) a CDRH2 that differs by no more than three amino acid substitutions, insertions and/or deletions from a CDRH2 as shown in TABLE 3;   c) a CDRH3 that differs by no more than three amino acid substitutions, insertions and/or deletions from a CDRH3 as shown in TABLE 3; and   comprising at least one light chain variable region comprising a CDRL1, a CDRL2 and a CDRL3 selected from the group consisting of:   d) a CDRL1 that differs by no more than three amino acid substitutions, insertions and/or deletions from a CDRL1 as shown in TABLE 3;   e) a CDRL2 that differs by no more than one amino acid substitution, insertion or deletion from a CDRL2 as shown in TABLE 3;   f) a CDRL3 that differs by no more than one amino acid substitution, insertion or deletion from a CDRL3 as shown in TABLE 3.   
     
     
         2 . An isolated antigen binding protein of  claim 1 , comprising at least one heavy chain variable region comprising a CDRH1, a CDRH2 and a CDRH3 selected from the group consisting of:
 a) a CDRH1 that differs by no more than one amino acid substitution, insertion or deletion from a CDRH1 as shown in TABLE 3;   b) a CDRH2 that differs by no more than two amino acid substitutions, insertions and/or deletions from a CDRH2 as shown in TABLE 3;   c) a CDRH3 that differs by no more than two amino acid substitutions, insertions and/or deletions from a CDRH3 as shown in TABLE 3; and   also comprising at least one light chain variable region comprising a CDRL1, a CDRL2 and a CDRL3 selected from the group consisting of:   d) a CDRL1 that differs by no more than two amino acid substitutions, insertions and/or deletions from a CDRL1 as shown in TABLE 3;   e) a CDRL2 that differs by no more than one amino acid substitution, insertions or deletion from a CDRL2 as shown in TABLE 3;   f) a CDRL3 that differs by no more than one amino acid substitution, insertions or deletion from a CDRL3 as shown in TABLE 3.   
     
     
         3 . An isolated antigen binding protein of  claim 1 , comprising at least one heavy chain variable region comprising a CDRH1, CDRH2 and a CDRH3 selected from the group consisting of:
 a) a CDRH1 that differs by no more than one amino acid substitution, insertion or deletion from a CDRH1 as shown in TABLE 3;   b) a CDRH2 that differs by no more than one amino acid substitution, insertion or deletion from a CDRH2 as shown in TABLE 3;   c) a CDRH3 that differs by no more than one amino acid substitution, insertion or deletion from a CDRH3 as shown in TABLE 3; and   also comprising at least one light chain variable region comprising a CDRL1, a CDRL2 and a CDRL3 selected from the group consisting of:   d) a CDRL1 that differs by no more than one amino acid substitution, insertion or deletion from a CDRL1 as shown in TABLE 3;   e) a CDRL2 that differs by no more than one amino acid substitution, insertion or deletion from a CDRL2 as shown in TABLE 3;   f) a CDRL3 that differs by no more than one amino acid substitution, insertion or deletion from a CDRL3 as shown in TABLE 3.   
     
     
         4 . An isolated antigen binding protein that binds IL-23 selected from the group consisting of
 a) an antigen binding protein having CDRH1 of SEQ ID NO:129, CDRH2 of SEQ ID NO:132, CDRH3 of SEQ ID NO:136, and CDRL1 of SEQ ID NO:123, CDRL2 of SEQ ID NO:81, and CDRL3 of SEQ ID NO: 76;   b) an antigen binding protein having CDRH1 of SEQ ID NO:131, CDRH2 of SEQ ID NO: 134, CDRH3 of SEQ ID NO:137 and CDRL1 of SEQ ID NO:124, CDRL2 of SEQ ID NO126 and CDRL3 of SEQ ID NO:128;   c) a) an antigen binding protein having CDRH1 of SEQ ID NO:130, CDRH2 of SEQ ID NO:133, CDRH3 of SEQ ID NO:99 and CDRL1 of SEQ ID NO:68, CDRL2 of SEQ ID NO:69, and CDRL3 of SEQ ID NO:67; and   d) an antigen binding protein having CDRH1 SEQ ID NO:91, CDRH2 SEQ ID NO: 135, CDRH3 SEQ ID NO:138 and CDRL1 SEQ ID NO:125, CDRL2 SEQ ID NO:127, and CDRL3 SEQ ID NO:64.   
     
     
         5 . An isolated antigen binding protein of  claim 1  comprising:
 a CDRH1 selected from the group consisting of SEQ ID NO: 91, 94, 97, 100, and 103; 
 a CDRH2 selected from the group consisting of SEQ ID NO:92, 95, 98, 101, 104, 107, and 110; 
 a CDRH3 selected from the group consisting of SEQ ID NO: 93, 96, 99, 102, and 105; 
 a CDRL1 selected from the group consisting of SEQ ID NO: 62, 65, 68, 71, and 74; 
 a CDRL2 selected from the group consisting of SEQ ID NO:63, 66, 69, 72, 75, and 78; and 
 a CDRL3 selected from the group consisting of SEQ ID NO:64, 67, 70 and 73. 
 
     
     
         6 . An isolated antigen binding protein of  claim 1 , comprising:
 a CDRH1 selected from the group consisting of SEQ ID NO: 91, 106, 109, 112, and 115;   a CDRH2 selected from the group consisting of SEQ ID NO: 113, 116, 118, 120, 121, and 122;   a CDRH3 selected from the group consisting of SEQ ID NO: 108, 111, 114, 117, and 119;   a CDRL1 selected from the group consisting of SEQ ID NO: 77, 80, 83, 85, 86, 87, 88, 89 and 90;   a CDRL2 is SEQ ID NO: 81; and   a CDRL3 selected from the group consisting of SEQ ID NO: 76, 79, 82 and 84.   
     
     
         7 . An isolated antigen binding protein that binds IL-23 comprising at least one heavy chain variable region and at least one light chain variable region, selected from the group consisting of:
 a) a heavy chain variable region comprising amino acid residues 31-35, 50-65 and 99-113 of SEQ ID NO:31; and
 a light chain variable region comprising amino acid residues 23-36, 52-58 and 91-101 of SEQ ID NO:1; 
   b) a heavy chain variable region comprising amino acid residues 31-35, 50-65 and 99-110 of SEQ ID NO:34 and heavy chain variable region comprising amino acid residues 31-35, 50-66 and 99-110 of SEQ ID NO:36; and
 a light chain variable region comprising amino acid residues 23-36, 52-62 and 97-105 of SEQ ID NO:4; 
   c) a heavy chain variable region comprising amino acid residues 31-35, 50-66 and 99-114 of SEQ ID NO:38; and
 a light chain variable region comprising amino acid residues 23-34, 50-61 and 94-106 of SEQ ID NO:7; 
   d) a heavy chain variable region comprising amino acid residues 31-35, 50-66 and 99-114 of SEQ ID NO:40; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 94-106 of SEQ ID NO:9; 
   e) a heavy chain variable region comprising amino acid residues 31-35, 50-66 and 99-114 of SEQ ID NO:42; and
 a light chain variable region comprising amino acid residues 23-34, 50-61 and 94-106 of SEQ ID NO:11; 
   f) a heavy chain variable region comprising amino acid residues 31-35, 50-65 and 98-107 of SEQ ID NO:44; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 89-97 of SEQ ID NO:13; 
   g) a heavy chain variable region comprising amino acid residues 31-37, 52-67 and 100-109 of SEQ ID NO:46 or 153; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 89-97 of SEQ ID NO15; 
   h) a heavy chain variable region comprising amino acid residues 31-37, 52-67 and 100-109 of SEQ ID NO:48; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 89-97 of SEQ ID NO:17; 
   i) a heavy chain variable region comprising amino acid residues 31-37, 52-67 and 101-109 of SEQ ID NO:50; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 89-97 of SEQ ID NO:19; 
   j) a heavy chain variable region comprising amino acid residues 31-35, 50-65 and 98-107 of SEQ ID NO: 52; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 98-107 of SEQ ID NO:21; 
   k) a heavy chain variable region comprising amino acid residues 31-37, 52-67 and 100-109 of SEQ ID NO:54; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 89-97 of SEQ ID NO:23; 
   l) a heavy chain variable region comprising amino acid residues 31-37, 52-67 and 100-109 of SEQ ID NO:56; and
 a light chain variable region comprising amino acid residues 24-34, 50-56 and 89-97 of SEQ ID NO:25; and 
   m) a heavy chain variable region comprising amino acid residues 31-37, 52-57 and 100-109 of SEQ ID NO:58; and
 a light chain variable region comprising amino acid residues 24-34, 500-56 and 89-97 of SEQ ID NO:27. 
   
     
     
         8 . An isolated antigen-binding protein of  claim 1  that comprises at least one heavy chain variable region and at least one light chain variable region. 
     
     
         9 . An isolated antigen-binding protein of  claim 1  that comprises at least two heavy chain variable regions and at least two light chain variable regions. 
     
     
         10 . An isolated antigen binding protein that binds IL-23 comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence differs by no more than 13 amino acid substitutions, additions and/or deletions from a heavy chain variable region sequence as shown in TABLE 2; and wherein the light chain variable region sequence differs by no more than 13 amino acid substitutions, additions and/or deletions from a light chain variable region sequence as shown in TABLE 1. 
     
     
         11 . An isolated antigen binding protein of  claim 10 , wherein the heavy chain variable region sequence differs by no more than 11 amino acid substitutions, insertions and/or deletions from a heavy chain variable region sequence as shown in TABLE 2. 
     
     
         12 . An isolated antigen binding protein of  claim 10 , wherein the heavy chain variable region sequence differs by no more than 5 amino acid substitutions, insertions and/or deletions from a heavy chain variable region sequence as shown in TABLE 2. 
     
     
         13 . An isolated antigen binding protein of  claim 10 , wherein the heavy chain variable region sequence differs by no more than 2 amino acid substitutions, insertions and/or deletions from a heavy chain variable region sequence as shown in TABLE 2. 
     
     
         14 . An isolated antigen binding protein of  claim 10 , wherein the heavy chain variable region sequence differs by no more than 1 amino acid substitution, insertion or deletion from a heavy chain variable region sequence as shown in TABLE 2. 
     
     
         15 . An isolated antigen binding protein of  claim 10 , wherein the light chain variable region sequence differs by no more than 7 amino acid substitutions, insertions and/or deletions from a light chain variable region sequence as shown in TABLE 1. 
     
     
         16 . An isolated antigen binding protein of  claim 10 , wherein the light chain variable region sequence differs by no more than 4 amino acid substitutions, insertions and/or deletions from a light chain variable region sequence as shown in TABLE 1. 
     
     
         17 . An isolated antigen binding protein of  claim 10 , wherein the light chain variable region sequence differs by no more than 2 amino acid substitutions, insertions and/or deletions from a light chain variable region sequence as shown in TABLE 1. 
     
     
         18 . An isolated antigen binding protein of  claim 10 , wherein the light chain variable region sequence differs by no more than 1 amino acid substitutions, insertions and/or deletions from a light chain variable region sequence as shown in TABLE 1. 
     
     
         19 . An isolated antigen binding protein that binds IL-23 selected from the group consisting of
 a) a heavy chain variable region of SEQ ID NO:140 and a light chain variable region of SEQ ID NO: 30;   b) a heavy chain variable region of SEQ ID NO:141 and a light chain variable region of SEQ ID NO:61;   c) a heavy chain variable region of SEQ ID NO:142 and a light chain variable region of SEQ ID NO:4; and   d) a heavy chain variable region of SEQ ID NO:143 and a light chain variable region of SEQ ID NO:139.   
     
     
         20 . An isolated antigen binding protein that binds IL-23 comprising
 a heavy chain variable region comprising of an amino acid sequence having at least 90% sequence identity to SEQ ID NO:31, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56 and 58; and   a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, 4, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27.   
     
     
         21 . An isolated antigen binding protein of  claim 20 ,
 a heavy chain variable region comprising of an amino acid sequence having at least 95% sequence identity to SEQ ID NO:31, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56 and 58; and   a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1, 4, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27.   
     
     
         22 . An isolated antigen binding protein of  claim 20 , comprising
 a heavy chain variable region comprising of an amino acid sequence having at least 97% sequence identity to SEQ ID NO:31, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56 and 58; and   a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 1, 4, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27.   
     
     
         23 . An isolated antigen binding protein of  claim 20 , comprising
 a heavy chain variable region comprising of an amino acid sequence having at least 98% sequence identity to SEQ ID NO:31, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56 and 58; and   a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 1, 4, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27.   
     
     
         24 . An isolated antigen binding protein of  claim 20 , comprising
 a heavy chain variable region selected from the group consisting of SEQ ID NO: 44, 46, 48, 50, 52, 54, 56, 58 and 153, and   a light chain variable region selected from the group consisting of SEQ ID NO:13, 15, 17, 19, 21, 23, 25, and 27.   
     
     
         25 . An isolated antigen binding protein of  claim 20 , comprising
 a heavy chain variable region selected from the group consisting of SEQ ID NO: 31, 34, 36, 38, 40 and 42, and   a light chain variable region selected from the group consisting of SEQ ID NO: 1, 4, 7, 9 and 11.   
     
     
         26 . An isolated antigen binding protein that binds IL-23 comprising a heavy chain variable region and a light chain variable region selected from the group consisting of:
 a) a heavy chain variable region of SEQ ID NO:31 and a light chain variable region of SEQ ID NO:1;   b) a heavy chain variable region of SEQ ID NO:34 or 36 and a light chain variable region of SEQ ID NO:4;   c) a heavy chain variable region of SEQ ID NO:38 and a light chain variable region of SEQ ID NO: 7;   d) a heavy chain variable region of SEQ ID NO:40 and a light chain variable region of SEQ ID NO:9;   e) a heavy chain variable region of SEQ ID NO:42 and a light chain variable region of SEQ ID NO: 11;   f) a heavy chain variable region of SEQ ID NO:44 and a light chain variable region of SEQ ID NO:13;   g) a heavy chain variable region of SEQ ID NO:46 or 153 and a light chain variable region of SEQ ID NO:15;   h) a heavy chain variable region of SEQ ID NO:48 and a light chain variable region of SEQ ID NO:17;   i) a heavy chain variable region of SEQ ID NO:50 and a light chain variable region of SEQ ID NO: 19;   j) a heavy chain variable region of SEQ ID NO:52 and a light chain variable region of SEQ ID NO:21;   k) a heavy chain variable region of SEQ ID NO:54 and a light chain variable region of SEQ ID NO:23;   l) a heavy chain variable region of SEQ ID NO:56 and a light chain variable region of SEQ ID NO:25; and   m) a heavy chain variable region of SEQ ID NO:58 and a light chain variable region of SEQ ID NO:27.   
     
     
         27 . An isolated antigen binding protein that binds human IL-23, wherein the covered patch formed when said antigen binding protein is bound to human IL-23 comprises residue contacts 30, 31, 32, 49, 50, 52, 53, 56, 92 and 94 of SEQ ID NO:15, wherein said residue contacts have a difference value of greater than or equal to 10 Å 2  as determined by solvent exposed surface area. 
     
     
         28 . An isolated antigen binding protein that binds human IL-23, wherein the covered patch formed when said antigen binding protein is bound to human IL-23 comprises residue contacts 31-35, 54, 58-60, 66, and 101-105 of SEQ ID NO:46, wherein said residue contacts have a difference value of greater than or equal to 10 Å 2  as determined by solvent exposed surface area. 
     
     
         29 . An isolated antigen binding protein that binds human IL-23, wherein the covered patch formed when said antigen binding protein is bound to human IL-23 comprises residue contacts 31-34, 51, 52, 55, 68, 93 and 98 of SEQ ID NO:1, wherein said residue contacts have a difference value of greater than or equal to 10 Å 2  as determined by solvent exposed surface area. 
     
     
         30 . An isolated antigen binding protein that binds human IL-23, wherein the covered patch formed when said antigen binding protein is bound to human IL-23 comprises residue contacts 1, 26, 28, 31, 32, 52, 53, 59, 76, 101, 102 and 104-108 of SEQ ID NO:31, wherein said residue contacts have a difference value of greater than or equal to 10 Å 2  as determined by solvent exposed surface area. 
     
     
         31 . An isolated antigen binding protein that binds human IL-23, wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 32-35, 54, 58-60, 66 and 101-105 of SEQ ID NO:46, as determined by X-ray crystallography. 
     
     
         32 . An isolated antigen binding protein according to  claim 31 , wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 31-35, 54, 56, 58-60, 66 and 101-105 of SEQ ID NO:46. 
     
     
         33 . An isolated antigen binding protein that binds human IL-23, wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 30-32, 49, 52, 53, 91-94 and 96 of SEQ ID NO:15, as determined by X-ray crystallography. 
     
     
         34 . An isolated antigen binding protein according to  claim 33 , wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 30-32, 49, 50, 52, 53, 56, 91-94 and 96 of SEQ ID NO:15. 
     
     
         35 . An isolated antigen binding protein that binds human IL-23, wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 26-28, 31, 53, 59, 102 and 104-108 of SEQ ID NO:31, as determined by X-ray crystallography. 
     
     
         36 . An isolated antigen binding protein according to  claim 35 , wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 1, 26-28, 30-32, 52, 53, 59, 100, and 102-108 of SEQ ID NO:31. 
     
     
         37 . An isolated antigen binding protein that binds human IL-23, wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 31-34, 51, 52, 55, 68 and 93 of SEQ ID NO:1 as determined by X-ray crystallography. 
     
     
         38 . An isolated antigen binding protein according to  claim 37 , wherein when said antigen binding protein is bound to human IL-23, said antigen binding protein is 5 Å or less from residues 29, 31-34, 51, 52, 55, 68, 93 and 100 of SEQ ID NO:1. 
     
     
         39 . An isolated antigen binding protein of  claim 1 ,  4 ,  7 ,  10 ,  19 ,  20 ,  26 - 31 ,  33 ,  35  or  37 , wherein said antigen binding protein is an antibody. 
     
     
         40 . An isolated antigen binding protein of  claim 39 , wherein said antibody is a monoclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof. 
     
     
         41 . An isolated antigen binding protein of  claim 40 , wherein said antibody fragment is a Fab fragment, a Fab′ fragment, a F(ab′) 2  fragment, a Fv fragment, a diabody, or a single chain antibody molecule. 
     
     
         42 . An isolated antigen binding protein of  claim 40 , wherein said antigen binding protein is a human antibody. 
     
     
         43 . An isolated antigen binding protein of  claim 40 , wherein said antigen binding protein is a monoclonal antibody. 
     
     
         44 . An isolated antigen binding protein of  claim 39 , wherein said antigen binding protein is of the IgG1-, IgG2-IgG3- or IgG4-type. 
     
     
         45 . An isolated antigen binding protein of  claim 44 , wherein said antigen binding protein is of the IgG1- or IgG2-type. 
     
     
         46 . An isolated nucleic acid molecule encoding an antigen binding protein of  claim 1 ,  4 ,  7 ,  10 ,  19 ,  20  or  26 . 
     
     
         47 . An isolated nucleic acid molecule of  claim 46 , wherein at least one heavy chain variable region is encoded by an isolated nucleic acid molecule selected from the group consisting of SEQ ID NOs:32, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59 and 152 and at least one light chain variable region is encoded by an isolated nucleic acid molecule selected from the group consisting of SEQ ID NOs:2, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28. 
     
     
         48 . A nucleic acid molecule according to  claim 47 , wherein said nucleic acid molecule is operably linked to a control sequence. 
     
     
         49 . A vector comprising a nucleic acid molecule according to  claim 46 . 
     
     
         50 . A host cell comprising the nucleic acid molecule according to  claim 46 . 
     
     
         51 . A host cell comprising the vector according to  claim 49 . 
     
     
         52 . An isolated polynucleotide sufficient for use as a hybridization probe, PCR primer or sequencing primer that is a fragment of the nucleic acid molecule of  claim 47  or its complement. 
     
     
         53 . A method of making the antigen binding protein of  claim 1 ,  4 ,  7 ,  10 ,  19 ,  20  or  26  comprising the step of preparing said antigen binding protein from a host cell that secretes said antigen binding protein. 
     
     
         54 . An isolated antigen binding protein that binds human IL-23, wherein the covered patch formed when said antigen binding protein is bound to human IL-23 comprises a residue contact within residues 46-58, a residue contact within residues 112-120, and a residue contact within residues 155-163 of the human IL-23p19 subunit as described in SEQ ID NO:145, wherein said residue contact has a difference value greater than or equal to 10 Å 2  as determined by solvent exposed surface area. 
     
     
         55 . An isolated antigen binding protein according to  claim 54 , wherein the covered patch formed when said antigen binding protein binds to human IL-23 further comprises a residue contact within residues 121-125 of the human IL-23p40 subunit as described in SEQ ID NO:147, wherein said residue contact has a difference value greater than or equal to 10 Å 2  as determined by solvent exposed surface area. 
     
     
         56 . An isolated antigen binding protein that binds human IL-23, wherein when said antigen binding protein is bound to human IL-23 said antigen binding protein is 5 Å or less from a residue within residues 46-58, from a residue within residues 112-123, and from a residue within residues 155-163 of the human IL-23p19 subunit as described in SEQ ID NO:145, as determined by X-ray crystallography. 
     
     
         57 . An isolated antigen binding protein according to  claim 56 , wherein when said antigen binding protein is bound to human IL-23 said antigen binding protein is 5 Å or less from a residue within residues 121-125, of the human IL-23p40 subunit as described in SEQ ID NO:147, as determined by X-ray crystallography. 
     
     
         58 . An isolated antigen binding protein of  claim 1 ,  4 ,  7 ,  10 ,  19 ,  20 ,  26 - 31 ,  33 ,  35 ,  37 ,  54  or  56  wherein said antigen binding protein has at least one property selected from the group consisting of:
 a) reducing human IL-23 activity; 
 b) reducing production of a proinflammatory cytokine; 
 c) binding to human IL-23 with a K D  of ≤5×10 −8  M; 
 d) having a K off  rate of ≤5×10 −6  1/s; and 
 e) having an IC 50  of ≤400 pM. 
 
     
     
         59 . A pharmaceutical composition comprising at least one antigen binding protein of  claim 1 ,  4 ,  7 ,  10 ,  19 ,  20  or  26  and pharmaceutically acceptable excipient. 
     
     
         60 . A pharmaceutical composition of  claim 59 , further comprises a labeling group or an effector group. 
     
     
         61 . A pharmaceutical composition of  claim 60 , wherein said labeling group is selected from the group consisting of isotopic labels, magnetic labels, redox active moieties, optical dyes, biotinylated groups and predetermined polypeptide epitopes recognized by a secondary reporter. 
     
     
         62 . A pharmaceutical composition of  claim 60 , wherein said effector group is selected from the group consisting of a radioisotope, radionuclide, a toxin, a therapeutic group and a chemotherapeutic group. 
     
     
         63 . An isolated antigen binding protein of  claim 60 , wherein said antigen binding protein is coupled to a labeling group. 
     
     
         64 . A method for treating or preventing a condition associated with IL-23 in a patient, comprising administering to a patient in need thereof an effective amount of at least one isolated antigen binding protein of  claim 1 ,  4 ,  7 ,  10 ,  19 ,  20  or  26 . 
     
     
         65 . A method of  claim 64 , wherein the condition is selected from the group consisting of an inflammatory disorder, a rheumatic disorder, an autoimmune disorder, an oncological disorder and a gastrointestinal disorder. 
     
     
         66 . A method of  claim 65 , wherein the condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, cancer, psoriasis, inflammatory bowel disease, Crohn&#39;s disease, ulcerative colitis, systemic lupus erythematosus, psoriatic arthritis, autoimmune myocarditis; type 1 diabetes and ankylosing spondylitis. 
     
     
         67 . A method of  claim 64 , wherein the isolated antigen-binding protein is administered alone or as a combination therapy. 
     
     
         68 . A method of reducing IL-23 activity in a patient comprising administering an effective amount of at least one antigen binding protein of  claim 1 ,  4 ,  7 ,  10 ,  19 ,  20  or  26 . 
     
     
         69 . A method of reducing IL-23 activity of  claim 68 , wherein said IL-23 activity is inducing production of a proinflammatory cytokine.
Join the waitlist — get patent alerts

Track US2020181255A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.